Table 3 Association of antihypertensive drugs, BPV status, and mortality

From: Therapeutic target and clinical impact of day-to-day blood pressure variability in hypertensive patients with covid-19

 

Low BPV

High BPV

p value

Antihypertension drug monoteraphy

  Beta Blockers

25%

75%

0.005

  CCBs Non DHP

16.7%

83.3%

  CCBs DHP

63.6%

36.4%

  ACEi

13.3%

86.7%

  ARB

88.9%

11.1%

Antihypertension drug combination teraphy

  ACEi/ARB + CCB

61.5%

38.5%

0.084

  ACEi/ARB + Diuretic

25%

75%

  ACEi/ARB + BB

40%

60%

  BB + Diuretic

25%

75%

  CCBs + Diuretic

83%

16,7%

CCB DHP medication

  CCB DHP

66.7%

33.3%

0.004

  Other antihypertensive drugs

33%

67%

 Mortality

  Death

71.7%

28.3%

0.000

  Survive

28.3%

41.7%

  1. ACEis angiotensin converting enzyme inhibitors, ARBs angiotensin receptor blockers, CCBs calcium channel blockers, DHP Dihidropyridin